________________________________________________________________________________________________________________________________

February 2010. What requirements stem technologies have to fulfil? What is the relationship to biomarker development? Which types of stem cells are most promising in order to meet Sanofi-Aventis’ strategic development goals? Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville (FR) describes in the interview with B2Bioworld, how his company approaches stem cells (including iPS cells), the role of small molecule development, and demand for complementary technologies.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Article free of advertisement - 5 pages
- Includes Sanofi-Aventis R&D Pipeline January 2010

Full Company License enquire here

Back to section

Related Editorial Articles

Transition: Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Leroy Hood: Thinking Further about Stem Cells

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

L'Oréal Makes Progress in Stem Cell Research

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Patenting Stem Cells - Behind the Front Stages

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Systems Biology In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts